Please provide your email address to receive an email when new articles are posted on . The PatientInsights 28-question survey from Phreesia was offered to patients with COPD in January 2025. Patients ...
Chronic obstructive pulmonary disease, or COPD, is the fourth leading cause of death worldwide, responsible for 3.5 million deaths in 2021, according to the World Health Organization. It’s a common ...
Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken a hit after the anti-ST2 monoclonal antibody failed to reduce flare-ups in ...
COPD Infection Management and Mitigation Strategies: Focusing on Diagnostics and Targeted Treatments
As the “Swiss Army knife of bacteria,” methicillin-resistant Staphylococcus aureus is quite the problematic organism, said John Osiecki, PhD. Among the diverse group of gram-positive bacteria ...
Biologic medicines are making inroads into chronic obstructive pulmonary disease (COPD), with two blockbuster antibodies expanding their FDA-approved uses to this lung disorder in the past year. A ...
Researchers conducted a prospective randomized controlled trial in 74 patients with stage III-IV COPD and prior hospitalization to assess the safety and efficacy of using telemedicine for follow-up.
David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...
Novel anti-ST2 monoclonal antibody astegolimab modestly reduced chronic obstructive pulmonary disease (COPD) exacerbations in the phase IIb ALIENTO trial. The biologic dosed every 2 weeks reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback